AUS
NZ
UK
CA
USA
IND
Healthcare
Telix Pharmaceuticals within ASX 200 Draws Focus as Market Reacts to RBA Move
February 03, 2026 04:23 PM AEDT| By SamTelix Pharmaceuticals remains a notable healthcare presence within major Australian indices as governance updates and monetary policy direction shape broader market structure.
Doctor Care Anywhere (ASX:DOC) Moves With All Ordinaries Index
February 03, 2026 04:16 PM AEDT| By SamAn overview of Doctor Care Anywhere Group PLC covering digital healthcare operations, operating balance progress, and sector context, with reference to All Ordinaries and broader Australian equity benchmarks.
Healthcare diagnostics activity framed within the All Ordinaries
February 03, 2026 12:01 PM AEDT| By SamHealthcare diagnostics operations outlined within the All Ordinaries, detailing manufacturing coordination and regulated participation in the Australian listed market.
All Ordinaries context shapes Doctor Care Anywhere healthcare operations
February 03, 2026 11:22 AM AEDT| By SamHealthcare sector content outlining digital service delivery by Doctor Care Anywhere within the All Ordinaries and the regulated Australian listed market framework.
All Ordinaries context frames Australian biotech neurological work
February 02, 2026 06:56 PM AEDT| By SamBiotechnology sector content outlining neurological research activity within the All Ordinaries and the structured framework of the Australian listed healthcare market.
All Ordinaries context surrounds Antares Metals Western Australia entry
February 02, 2026 02:11 PM AEDT| By SamMaterials sector content describing Antares Gold’s Western Australia asset participation within the All Ordinaries and the regulated Australian listed market framework.
Prescient Therapeutics Within All Ordinaries Biotechnology Landscape
January 30, 2026 04:42 PM AEDT| By SamPrescient Therapeutics advanced clinical biotechnology activity through European regulatory authorisations while maintaining participation within the All Ordinaries healthcare sector.
ASX 200 Healthcare Framework Reflects Ansell Operational Presence
January 30, 2026 03:17 PM AEDT| By SamAnsell maintained healthcare manufacturing and safety equipment operations while participating within the ASX 200 and All Ordinaries market framework.
Oneview Healthcare Outlook on the ASX Market: A Long-Term Growth Narrative
January 30, 2026 12:40 PM AEDT| By SamOneview Healthcare reflects the growing role of digital platforms in healthcare, highlighting long-term relevance within Australia’s evolving equity market landscape.
AdAlta’s Capital Expansion Move: What It Signals for Market Watchers
January 30, 2026 12:11 PM AEDT| By SamAdAlta’s capital update highlights strategic planning within Australia’s evolving equity landscape, reflecting broader trends in innovation-driven market participation.
AdAlta’s ASX Update Sparks Fresh Market Attention in Australia
January 30, 2026 12:07 PM AEDT| By SamAdAlta’s market update reflects strategic capital positioning, reinforcing its presence within Australia’s evolving healthcare and equity landscape.
Mesoblast (ASX:MSB) Expands Ryoncil Adoption and Adult Trials
January 29, 2026 06:20 PM AEDT| By SamMesoblast (ASX:MSB) expands Ryoncil adoption in pediatric and adult patients, advancing cell therapies for severe conditions and chronic pain, highlighting growth in innovative healthcare solutions.
Lumos Diagnostics (ASX:LDX) Accelerates FebriDx Rollout with US Growth Surge
January 29, 2026 05:53 PM AEDT| By SamLumos Diagnostics expands FebriDx adoption in the US and globally, advancing regulatory approvals, Medicare reimbursement, and paediatric studies while strengthening commercial execution.
Cell Therapy Development Update Places Arovella Therapeutics in All Ordinaries
January 29, 2026 05:31 PM AEDT| By SamArovella Therapeutics achieved regulatory clearance for its ALA one zero one program, supporting progression toward initial clinical evaluation and reinforcing its presence within the All Ordinaries.
Healthcare Innovation Draws Attention Across ASX 100 Landscape
January 29, 2026 04:33 PM AEDT| By SamAustralian biotechnology activity gained attention following a detailed quarterly update, highlighting healthcare research progress across major ASX indices.
ASX 200 Focus: ECS Botanics Suspension Update Reshapes Biotechnology Landscape
January 29, 2026 04:25 PM AEDT| By SamASX applies a quotation suspension to an ECS Botanics security class, highlighting regulatory processes that support transparency across Australian biotechnology listings.
Island Pharma (ASX:ILA) Flat as All Ordinaries Index Steady
January 29, 2026 04:24 PM AEDT| By SamAn overview of Island Pharmaceuticals Limited within the All Ordinaries, covering antiviral research orientation, biotechnology sector positioning, and operational structure.
CSL (ASX:CSL) in Focus as Results and Seqirus Updates Shape Market Attention
January 29, 2026 03:56 PM AEDT| By SamAn in-depth look at CSL (ASX:CSL) as half-year results approach, exploring Seqirus developments, healthcare sector trends, and how broader movements in the Australian stock market influence sentiment.
ASX 200 Watch: Why CSL’s Market Story Is Drawing Fresh Attention
January 29, 2026 02:36 PM AEDT| By SamCSL remains a central figure in ASX market discussions as healthcare regains attention, reflecting long-term sector strength and evolving investor priorities.
Market Activity Surrounds BPH Global Across All Ordinaries
January 29, 2026 12:08 PM AEDT| By SamBPH Global recorded notable trading activity influenced by liquidity conditions, highlighting its position within the All Ordinaries and the broader Australian listed market.
Advertise your brand on Kalkine Media